Anavex Life Sciences Corp (AVXL)

[falconer66a]

Implications, Revelations of Continued Australian Post-trial Dosing

Whether for physical or mental reasons, it seems the phase 2 participants have no desire to do without.

Yes, this is significant. After the initial safety and tolerability trial ended in Australia, after about a year, virtually all of those in the study elected to continue to receive Anavex 2-73 dosings. Moreover, after now, what, about two years after the formal study ended, participants continue to elect to take the drug. Why would so many do that?

Apparently, the drug causes few or mild side effects with continued, multi-year administration and consumption. The drug in this small population of Alzheimer’s patients appears to be profoundly safe. Listen to the long list of profound side effects for any of the so-wonderful drugs advertised on any of the national newscasts on TV each evening. Won’t be many of those when Anavex 2-73 gets FDA (or Australian) approval.

But lack of adverse events, side effects, cannot be why those Australian Alzheimer’s patients wished to, agreed to, continued to take the drug long after the clinical trial ended. Just a) why would they do that, and b) more importantly, why would Australian medical officials allow this?

Each pondering this phenomenon must decide for himself. For me, I can only presume the patients desired to continue with the drug, and stay with for so long, because it had some discernable benefits.

I can see only two categories of such: the patients either actually improved their cognition and general way-of-life abilities, or, at least, the drug kept symptoms from getting worse.

If it’s the first reason, people getting actually better with long-term Anavex 2-73 treatment, I needn’t lay out the multiple outcomes this will have.

But, it may be only that the drug stopped the progression of the disease. People headed for nursing homes and day-care centers retained enough normalized cognition to remain usefully in their own homes, cared for by family members.

I’m wondering how conditional continued dosing might be. “Matilda, we’ll continue to provide the drug, but only if you promise to say not a word to anyone about what it’s doing for you. Let any of that out, to even your neighbor or your aunt, and we cut off your supply immediately. It’s important that this information remain quiet for a while.”

If prophylaxis is the scenario, ponder the implications for Anavex Life Sciences Corp. Treat before severe. Treat before seen. Prevent Alzheimer’s before it starts. Hold it at bay after it starts.

Is Anavex 2-73 not only a neural rejuvenator (for those with a CNS disease), but also a neural disease preventer before getting a CNS disease?

The continued, long-term, post-clinical dosing of the Australians fits either of these scenarios.